To include your compound in the COVID-19 Resource Center, submit it here.

Product Development
Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

Carving a space in the crowded multiple myeloma market for recently approved Sarclisa is one of the four pillars of Sanofi’s strategy for re-entering oncology, and the company ...

Tools & Techniques
Spark’s approach to the problem of redosing AAV gene therapies

Spark aims to solve one of the big problems plaguing gene therapy -- immune responses against viral vectors -- by adapting a strategy Hansa has been developing for transplant ...

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC ...

Pfizer’s $500M public biotech fund to complement late-stage BD activity

Pfizer is bolstering future business development opportunities with a $500 million fund designed to take small to mid-cap public biotechs with early-stage clinical assets to their ...

Daily Chart: IPO queue grows to 20 life sciences companies

Twenty life sciences companies have lined up to make public debuts on U.S. and Asian exchanges, with Pliant Therapeutics

Read the full

June 2 Financial Quick Takes: follow-ons for Allogene, Adaptimmune, plus DCVC Bio, Windtree and BMS

Allogene raises $550M follow-on
Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $550 million late Monday through the sale of 11.7 million shares at $47, a 2% ...

BioCentury ISSN 1097-7201